AI-generated summary
The authors report a 12-month randomized trial of nightly low-level light therapy using a 505 nm light-emitting mask in 60 people with age-related macular degeneration, compared with an untreated control group. They found no substantial difference in disease progression between groups, and the intervention group showed a larger delay in cone dark adaptation. The authors also state the therapy was acceptable to patients and no adverse events were judged related to it.
- Participants
- 60
- Who or what was studied
- Adults aged 55 to 88 years with early age-related macular degeneration in the study eye and neovascular age-related macular degeneration in the fellow eye, recruited from a single hospital clinic
- Wavelengths
- 505 nm
- Limits stated in the abstract
- The abstract describes a single-center, unmasked, proof-of-concept trial with a small sample, and the authors note the dark adaptation effect's permanency and cause remain unknown.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on iovs.arvojournals.org.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 505 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Age-related macular degeneration, Control group, Randomized controlled trial, Confidence interval, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.